Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

ER study sheds light on hidden xylazine in opioid overdoses

NCT ID NCT06949605

Knowledge-focused Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study measured the amount of xylazine—a dangerous animal sedative often mixed with opioids—in the blood and urine of 75 emergency room patients who had a non-fatal opioid overdose. The goal was to see how common xylazine is and how well test strips can detect it. The findings could help emergency doctors better identify and respond to this growing threat.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors quickly detect xylazine in opioid overdoses and guide better emergency treatment.
What could go wrong
This was a small, observational study that only measured levels—it did not test any treatment or prove that detection improves outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

75 people

The number who actually took part.

Started

Apr 2025

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All participating sites will enroll all opioid ODs presenting to Mount Sinai Hospital and Elmhurst Hospital Emergency Departments, regardless of whether or not a consultation by a medical toxicologist was requested (i.e., all consecutive opioid ODs).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ED patient * Opioid OD (both NPS and non-NPS) * Availability of waste blood specimens for analysis * Availability of waste urine specimens for analysis Exclusion Criteria: \- Children under 18

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid overdose are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute opioid poisoning Opiate Overdose substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opioid overdose Substance use disorders

Contacts and locations

Locations

  • Icahn School of Medicine

    New York, New York, 10029, United States

  • NYC Health + Hospitals/Elmhurst

    Elmhurst, New York, 11373, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.